Incyte's most sold drug, Jakafi, increases the risk of anemia in patients already vulnerable to it
Register to read the full analysis —or— Upgrade to access more features
#illnesses
#side-effects
#negative health
#cancer
#anemia
Actual Direct Impact
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.